Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
100% intravenous; not administered by other routes.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No dosage adjustment required for hepatic impairment.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Not applicable; no FDA boxed warning exists for this product.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.